Peer-influenced content. Sources you trust. No registration required. This is HCN.
Psychiatrist.com
Although research exists on the impact of CNS stimulants used in pregnancy, only a few small studies have looked at atomoxetine and pregnancy outcomes. This large cohort study of 4.2 million pregnancies ending in live births in northern Europe and the US reviewed nearly 1,000 pregnancies exposed to atomoxetine in the first trimester. Compared with non-exposed pregnancies, there was no observed increase in major congenital abnormalities with atomoxetine use in the first trimester.
Internal Medicine January 18th 2023
Misuse of prescription stimulants was associated with prior year treatment for depression, ADHD, and substance use disorder. Identified risk factors for stimulant misuse include use of prescription drugs in the past month (5.5 times increased risk) and use of illegal drugs in the past month (8 times higher risk).
Psychiatry January 4th 2023
Pharmacy Practice News
Teva Pharmaceuticals is the primary supplier of both branded and generic versions of the stimulant, which is approved to treat ADHD and narcolepsy. Teva has cited increased demand, workforce shortages, and manufacturing disruptions due to packaging constraints as reasons for the supply problems.
Clinical Pharmacology October 27th 2022
Psych Congress Network
After reading this article, head over to this quiz to test your understanding of the findings of a triple-blind, crossover study that involved 173 ADHD-diagnosed children between the ages of 7 and 12. Children received daily education in science, social studies, and vocabulary for 25 minutes over the course of two successive sessions.
Pediatrics August 22nd 2022